• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION OBTRYX HALO; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR STRESS URINARY INCONTINENCE, RETR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION OBTRYX HALO; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR STRESS URINARY INCONTINENCE, RETR Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Bacterial Infection (1735); Cyst(s) (1800); Urinary Tract Infection (2120)
Event Date 08/31/2013
Event Type  Injury  
Event Description
On (b)(6), (b)(6) had surgery to treat stress urinary incontinence, with insertion of a sling by transobturator procedure.Three days after surgery, (b)(6) had a first cystitis (escherichia coli resistant to ampicillin and ticarcillin).Since then, she has recurrent utis, about one to 6 times per month.Most of the time, the bacteria is gram negative, escherichia coli being the most frequently found in cebus post-surgery in 2013 (16/22 documented cases).Other documented gram positive bacteria were staphylococcus epidermis (2/22), enterococcus faecalis (3/22), and staphylococcus saprophyticus (1/2).On the last cytobacteriological urinary examination performed on (b)(6) 2019, escherichia coli was found resistant to ampicillin, augmentin, selexid, fosfomycin and bactrim.This was consecutive to monitoring visits in (b)(6) hospitals.During the flu period's she has been treated with ofloxacin for 7 days.Since the surgery in 2013, (b)(6) has contacted 3 urologists and every time the answer was: "we can't remove the mesh".This information was not presented in the informed consent signed pre-surgery in 2013.This information is now present in the amended informed consent released in (b)(6) 2016.One proposal to solve the voiding problem was: self- performed intermittent catheterization.The second proposal was "see a psychiatrist".For one year and a half, (b)(6) has developed osteonecrosis of the left femoral head ( stage iv) and needs a surgery for hip prosthesis implantation.The surgeon wants to cure the colibacillosis before surgery.Fda safety report id # (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OBTRYX HALO
Type of Device
MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR STRESS URINARY INCONTINENCE, RETR
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
MDR Report Key8674797
MDR Text Key147452619
Report NumberMW5087154
Device Sequence Number1
Product Code OTN
Combination Product (y/n)N
Reporter Country CodeFR
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 06/01/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received06/05/2019
Was Device Evaluated by Manufacturer? No Information
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age50 YR
Patient Weight75
-
-